Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > current valuation

<< Previous

Bullboard Posts

Next >>

Comment by Straylighton Jan 26, 2021 9:10am

146 Views

Post# 32385742

RE:RE:current valuation

Yes they seem to be trying to apply some simple calculation based on income vs. expenses which doesnt really lend itself to companies generating IP at early stages.

Probably makes a lot more sense for established firms in more traditional sectors like banking, retail, or natural resources.

<< Previous

Bullboard Posts

Next >>

Unique Battery Metals opportunity in Quebec